Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.55 |
| ▸ | ITGB3 | P05106 | 10/20 | 0.53 |
| ▸ | ITGA2B | P08514 | 10/20 | 0.53 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18010773 | 0.88 | MAPT (0.46) | BRD4ITGB3ITGA2BSCN9AL3MBTL1 | |
| SCHEMBL18010765 | 0.84 | TSHR (0.47) | BRD4ITGB3ITGA2BTSHR | |
| SCHEMBL18010768 | 0.83 | RORC (0.51) | BRD4ITGB3ITGA2BTSHR | |
| SCHEMBL23768797 | 0.81 | BRD4 (0.58) | BRD4ITGB3ITGA2BSCN9AL3MBTL1 | |
| SCHEMBL755818 | 0.81 | SCN9A (0.56) | BRD4ITGB3ITGA2BSCN9AL3MBTL1 | |
| SCHEMBL19669647 | 0.81 | ITGB3 (0.63) | BRD4ITGB3ITGA2BSCN9AL3MBTL1 | |
| SCHEMBL18010670 | 0.81 | PLA2G7 (0.41) | BRD4ITGB3ITGA2BL3MBTL1 | |
| SCHEMBL18010855 | 0.81 | CHRM5 (0.43) | BRD4ITGB3ITGA2BTSHR | |
| SCHEMBL18010673 | 0.81 | RORC (0.39) | BRD4ITGB3ITGA2BTSHR | |
| SCHEMBL18497019 | 0.80 | BRD4 (0.58) | BRD4ITGB3ITGA2BSCN9AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9834520-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-12-05 | — | — | US | disclosed |
| US-20160229814-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160229814-A1 | HETEROCYCLIC COMPOUND | RORB, RORC, RORA | BRD4 30/4885ITGB3 2497/4885ITGA2B 1477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.